Sinae Kim1, Eun Sung Lee1, Eun Ji Lee1, Jae Yun Jung1, Sae Byul Lee2, Hee Jin Lee3, Jisun Kim2, Hee Jeong Kim2, Jong Won Lee2, Byung Ho Son2, Gyungyub Gong3, Sei-Hyun Ahn2, Suhwan Chang4. 1. Department of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, South Korea. 2. Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, South Korea. 3. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, South Korea. 4. Department of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, South Korea. suhwan.chang@amc.seoul.kr.
Abstract
BACKGROUND: Prostaglandin is one of the key metabolites for inflammation-related carcinogenesis. Despite the microRNA-155 is implicated in various types of cancers, it's function in prostaglandin metabolism is largely unknown. METHODS: A targeted profiling of eicosanoids including prostaglandin, leukotriene and thromboxanes was performed in miR-155 deficient breast tumors and cancer cells. The molecular mechanism of miR-155-mediated prostaglandin reprogramming was investigated in primary and cancer cell lines, by analyzing key enzymes responsible for the prostaglandin production. RESULTS: We found miR-155-deficient breast tumors, plasma of tumor-bearing mouse and cancer cells show altered prostaglandin level, especially for the prostaglandin E2 (PGE2) and prostaglandin D2 (PGD2). Subsequent analysis in primary cancer cells, 20 triple-negative breast cancer (TNBC) specimens and breast cancer cell lines with miR-155 knockdown consistently showed a positive correlation between miR-155 level and PGE2/PGD2 ratio. Mechanistically, we reveal the miR-155 reprograms the prostaglandin metabolism by up-regulating PGE2-producing enzymes PTGES/PTGES2 while down-regulating PGD2-producing enzyme PTGDS. Further, we show the up-regulation of PTGES2 is driven by miR-155-cMYC axis, whereas PTGES is transactivated by miR-155-KLF4. Thus, miR-155 hires dual-regulatory mode for the metabolic enzyme expression to reprogram the PGE2/PGD2 balance. Lastly, we show the miR-155-driven cellular proliferation is restored by the siRNA of PTGES1/2, of which expression also significantly correlates with breast cancer patients' survival. CONCLUSIONS: Considering clinical trials targeting PGE2 production largely have focused on the inhibition of Cox1 or Cox2 that showed cardiac toxicity, our data suggest an alternative way for suppressing PGE2 production via the inhibition of miR-155. As the antagomiR of miR-155 (MRG-106) underwent a phase-1 clinical trial, its effect should be considered and analyzed in prostaglandin metabolism in tumor.
BACKGROUND:Prostaglandin is one of the key metabolites for inflammation-related carcinogenesis. Despite the microRNA-155 is implicated in various types of cancers, it's function in prostaglandin metabolism is largely unknown. METHODS: A targeted profiling of eicosanoids including prostaglandin, leukotriene and thromboxanes was performed in miR-155deficient breast tumors and cancer cells. The molecular mechanism of miR-155-mediated prostaglandin reprogramming was investigated in primary and cancer cell lines, by analyzing key enzymes responsible for the prostaglandin production. RESULTS: We found miR-155-deficient breast tumors, plasma of tumor-bearing mouse and cancer cells show altered prostaglandin level, especially for the prostaglandin E2 (PGE2) and prostaglandin D2 (PGD2). Subsequent analysis in primary cancer cells, 20 triple-negative breast cancer (TNBC) specimens and breast cancer cell lines with miR-155 knockdown consistently showed a positive correlation between miR-155 level and PGE2/PGD2 ratio. Mechanistically, we reveal the miR-155 reprograms the prostaglandin metabolism by up-regulating PGE2-producing enzymes PTGES/PTGES2 while down-regulating PGD2-producing enzyme PTGDS. Further, we show the up-regulation of PTGES2 is driven by miR-155-cMYC axis, whereas PTGES is transactivated by miR-155-KLF4. Thus, miR-155 hires dual-regulatory mode for the metabolic enzyme expression to reprogram the PGE2/PGD2 balance. Lastly, we show the miR-155-driven cellular proliferation is restored by the siRNA of PTGES1/2, of which expression also significantly correlates with breast cancerpatients' survival. CONCLUSIONS: Considering clinical trials targeting PGE2 production largely have focused on the inhibition of Cox1 or Cox2 that showed cardiac toxicity, our data suggest an alternative way for suppressing PGE2 production via the inhibition of miR-155. As the antagomiR of miR-155 (MRG-106) underwent a phase-1 clinical trial, its effect should be considered and analyzed in prostaglandin metabolism in tumor.
Authors: Suhwan Chang; Rui-Hong Wang; Keiko Akagi; Kyung-Ae Kim; Betty K Martin; Luca Cavallone; Diana C Haines; Mark Basik; Phuong Mai; Elizabeth Poggi; Claudine Isaacs; Lai M Looi; Kein S Mun; Mark H Greene; Stephen W Byers; Soo H Teo; Chu-Xia Deng; Shyam K Sharan Journal: Nat Med Date: 2011-09-25 Impact factor: 53.440
Authors: Brian S Comer; Blanca Camoretti-Mercado; Paul C Kogut; Andrew J Halayko; Julian Solway; William T Gerthoffer Journal: Am J Respir Cell Mol Biol Date: 2015-04 Impact factor: 6.914
Authors: Yubin Hao; Xinbin Gu; Yuan Zhao; Stephen Greene; Wei Sha; Duane T Smoot; Joseph Califano; T-C Wu; Xiaowu Pang Journal: Cancer Prev Res (Phila) Date: 2011-03-23
Authors: D Jurkovicova; M Magyerkova; L Kulcsar; M Krivjanska; V Krivjansky; A Gibadulinova; I Oveckova; M Chovanec Journal: Neoplasma Date: 2014 Impact factor: 2.575
Authors: Kotha Subbaramaiah; Patrick G Morris; Xi Kathy Zhou; Monica Morrow; Baoheng Du; Dilip Giri; Levy Kopelovich; Clifford A Hudis; Andrew J Dannenberg Journal: Cancer Discov Date: 2012-01-27 Impact factor: 39.397
Authors: Konstantinos Stamatakis; Marta Jimenez-Martinez; Alba Jimenez-Segovia; Isabel Chico-Calero; Elisa Conde; Javier Galán-Martínez; Julia Ruiz; Alejandro Pascual; Beatriz Barrocal; Ricardo López-Pérez; María Laura García-Bermejo; Manuel Fresno Journal: Oncotarget Date: 2015-11-24
Authors: Valeria Villarreal-García; José Roberto Estupiñan-Jiménez; Pablo E Vivas-Mejía; Vianey Gonzalez-Villasana; José Manuel Vázquez-Guillén; Diana Reséndez-Pérez Journal: Front Oncol Date: 2022-09-26 Impact factor: 5.738